The instrument is made under the subsection 23DNA(1) power in the Health Insurance Act 1973, the same power that supports the 2017 Principles it amends.
What the provision does
Section 3 states the authority. The subsection 23DNA(1) power in the Health Insurance Act 1973 lets the Minister set out the principles that govern how the approval powers under section 23DN are exercised. The instrument is therefore a legislative instrument made under the Act, and it amends the Principles that the Minister applies when approving, refusing, varying or revoking an approval of premises as an accredited pathology laboratory. The Explanatory Statement records that the instrument is disallowable and that it is compatible with the human rights recognised in the Human Rights (Parliamentary Scrutiny) Act 2011.
Why it matters
The authority section answers a question that matters to a regulated entity: does this instrument impose a direct duty on the laboratory, or does it govern the Minister? The power is conferred on the Minister and the Principles are the principles the Minister applies. The laboratory meets the incorporated standards through accreditation by an independent body, and Medicare eligibility follows from the approval.
What changed, and when
Section 3 states the authority. It commenced with sections 1 to 4 on 13 July 2026. It does not itself amend a parent provision; it identifies the power under which the instrument is made.
This unit is one of the ten that commenced on 13 July 2026. It is not waiting for 1 July 2027. A record that treats it as future will describe the wrong approval process or the wrong edition at the next assessment.
What to do about it
Do not quote the instrument as if it directly commanded the laboratory. The amendment leaves a single approval pathway, not two. Describe the chain accurately: the Minister approves premises under section 23DN; the Principles set the criteria; Schedule 1 incorporates the standards; NATA assesses against them; the approval supports Medicare benefits. When a contract or a board paper describes the duty, use that chain. Keep the Act reference and the instrument reference together.
What the assessor asks for
| Category | Artefact to have ready |
|---|---|
| Legal register | The entry that records the Act, the section and the instrument, with the disallowable status noted |
| Board paper | The paragraph that describes the approval chain rather than asserting a direct statutory duty on the laboratory |
| Contract schedule | The accreditation warranty that names the standards and the approval route without misstating who made the instrument |
The question that follows. A lawyer or a regulator may ask whether the instrument binds the laboratory directly, and the accurate answer is that it governs the Minister and incorporates the assessment standards.
Gaps that lose a file
- Saying the instrument directly imposes duties on laboratories
- Citing the Act but not the instrument
- Forgetting that the instrument is disallowable
Before the date
- Add the authority chain to the compliance register
- Train the quality team to describe the route through NATA accreditation
- Keep the Explanatory Statement with the instrument in the legal file
Dates
| Date | What happens | Source pointer |
|---|---|---|
| Section 3 commences | s 2 table item 1 |
Cross-references
Name of the instrument · Schedules · The approval test
Source
Section 3. The operative text is F2026L00927 on the Federal Register, with the parent 2017 Principles and the Explanatory Statement. Our statement, not the instrument verbatim.
Not legal advice; does not certify. A reading of the provision and the evidence an assessor commonly samples, not a substitute for the instrument, the standards or your accreditation body's rules.